First AD

Second AD

Surbhi Sidana, MD, is an associate professor of medicine and associate director for Clinical Research in the Bone Marrow Transplantation and Cell Therapy Division at Stanford University in California.

Peter Voorhees, MD, is a member of the Hematology Department at Atrium Health Levine Cancer Institute and a professor of Cancer Medicine at the Wake Forest University School of Medicine in Charlotte, North Carolina.Peter Voorhees, MD

Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

Video content above is prompted by the following:

What is your clinical approach to CAR T-cell therapy in R/R MM? How are you typically sequencing CAR T with the other available treatment options like autologous HSCT and bispecifics?

Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

CAR T-cell Therapy in Multiple Myeloma: Finding Its Right Place 

OncLive Insights

Experts discuss their clinical approach to using chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM), focusing on how they sequence CAR T with other treatment options like autologous hematopoietic stem cell transplantation (HSCT) and bispecific antibodies.

Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection

Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

Strategic Timing for CAR T in R/R MM: The Importance of Early Referral

Bridging to CAR T in R/R MM: Best Practices

Explaining CAR T: Key Points for Patient Counseling

Overcoming Barriers to CAR T Referral in R/R MM

Collaborative Approach in Managing Post CAR T Care Between Academic and Community Physicians in R/R MM

Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM